Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of TLC-3595 in Subjects With Insulin Resistance

NCT05665751 is registered in ClinicalTrials.gov with OrsoBio, Inc as lead sponsor.

NCT NCT05665751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05665751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of TLC-3595 in Subjects With Insulin Resistance
Lead sponsor
OrsoBio, Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 8, 2023
Completion date
December 31, 2024
Enrollment
76 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

insulin resistance